tbuckley/cabot-search huggingface dataset:
High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment
Authors: Jana Jakubikova, Danka Cholujova, Gabor Beke, Zachary R Hunter, Teru Hideshima, Ludmila Flores, Merav Leiba, Paul G. Richardson, Eftathios Kastritis, David M. Dorfman, Steven P Treon, Kenneth C. Anderson
Journal: Blood (2019)
Desideromastica: Tactile Chew Cravings in Iron Deficiency Anemia
Authors: Caleb J Scheckel, Didar Yanardag Acik, Aneel A. Ashrani, C. Christopher Hook, Lindsey Ann Kluck, Ariela L. Marshall, Rajiv K. Pruthi, Aishwarya Ravindran, Mithun Vinod Shah, Alexandra Wolanskyj, Ronald S. Go
Journal: Blood (2019)
PDCT-04. ETMR ONE: AN INTERNATIONAL REGISTRY AND RESEARCH PLATFORM FOR CHILDREN WITH EMBRYONAL TUMOR WITH MULTILAYER ROSETTES
Authors: Derek Hanson
Journal: Neuro-Oncology (2019)

Abstract Embryonal tumor with multilayer rosettes (ETMR) is a rare and highly-aggressive CNS neoplasm which occurs almost exclusively in young children and is associated with an extremely poor prognosis. Due to the rare nature of ETMR and its recent classification, no large clinical investigations have been conducted to determine the optimal therapy for these tumors. Historical data suggests that extensive surgical resection, radiotherapy, and high-dose chemotherapy are not sufficient treatment in the vast majority of cases with a reported 1-year EFS of 36% and 1-year OS of 45% using these approaches. New treatment regimens incorporating the known biology of ETMR must be investigated. Pre-clinical drug screens using the ETMR BT183 cell line and its xenograft have demonstrated responses to the chemotherapy agents topotecan, doxorubicin, and actinomycin D. Based on this data, a modified IRS-III chemotherapy regimen incorporating these active agents was developed and a small cohort of four children with ETMR were then treated. Three patients completed therapy without subsequent relapse and have EFS of &gt;30 months. The ETMR One international registry and its associated consensus treatment protocol represent the first prospective evaluation of treatment outcomes for children with ETMR. The consensus regimen involves maximal feasible surgical resection, modified IRS-III chemotherapy, high-dose chemotherapy with autologous stem cell rescue, and radiotherapy (as indicated). Patients enrolled on the registry will have their cases periodically reviewed by a medical advisory board that will offer management recommendations, particularly regarding the use of radiotherapy or the need for additional surgical interventions. Through the procurement of patient tumor samples and development of additional cell lines and xenografts, the registry aims to serve as a platform for translational research. Pre-clinical findings will be used to modify the consensus protocol therapy as indicated or to generate additional biology-based phase I/II trials for ETMR.
Carcinoma of the Stomach
Authors: B. F. Swynnerton, S. C. Truelove
Journal: BMJ (1952)

Carcinoma of the stomach is one of the commonest neoplasms, and in 1949 accounted for the death of 8,096 men and 6,157 women (Registrar-General, 1951).It carries a bad prognosis, but examination of the literature reveals considerable discrepancies from one medical centre to another.We have therefore reviewed the experience of the Radcliffe Infirmary, which is well suited to this form of clinical study.Not only has it an efficient records department and a high standard of note-taking, but also, except in a few special branches of medicine, it functions as a community hospital and its patients are representative of the major illnesses in the area.We have studied the case notes of all in-patients who were diagnosed as suffering from gastric carcinoma during the period 1938-49 inclusive, and have followed their progress.With the help of Miss Eva Spitz, almoner to,the Nuffield Department of Clinical Medicine, and by making use of various sources of information-patients, relatives, friends, family doctors, food offices, and registrars of births and deaths-we have obtained satisfactory follow-up data in every case.The length of follow-up varies from 1 to 13 years.Age and Sex.-Nearly twice as many men as women were admitted with the disease.In both sexes the peak case incidence occurs in the sixties, which is somewhat later than is given by many writers.From Table I, which sets out the distribution of cases by age and sex, it will be seen that gastric carcinoma is uncommon below the age of 30.Relatively more of the men develop the disease below the age of 60 (49 % -of the men, as opposed to 39% of the women).However, the difference is only at the borderline of statistical significance, so that it is of doubtful importance, particularly as the general TABLE I.-Case Distribution by Age and Sex
Venous Assessment Prior to Mobilization Significantly Reduced Use of Apheresis Central Venous Catheters
Authors: Michele Boonstra, Melissa Baker, Tracy Andrews, Maria Cortes, Ann Marie Maguire, Sarina Torres, Joshua Zenreich, Lina Starovoitova, Scott D. Rowley, Alan P Skarbnik, Andrew L. Pecora, Andre Goy, David H. Vesole, Michele L. Donato
Journal: Blood (2016)
Bollous Lesions in Acute Barbiturate Intoxication
Authors: J. D. Spillane
Journal: BMJ (1965)

Africa's Need SIR,-Your leading article (10 April, p. 939) raises many points for those interested in medical care in the emergent countries of Africa.As regards the shortage of doctors, your remarks perhaps need qualifying.For a variety of reasons the extent of departure of expatriate doctors seems to have differed, and presumably has been marked from those
Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution
Authors: Jorge Monge, Kari Flicker, Danielle Guarneri, Robin S. Solomon, Jin Guo, Jorge Contreras, Natalie Agudo, David S Jayabalan, Kathleen Pogonowski, Brielle Liotta, Jingmei Hsu, Adrienne A. Phillips, Sebastian A. Mayer, Usama Gergis, Tsiporah B. Shore, Koen Van Besien, Morton Coleman, Cara A. Rosenbaum, Roger Pearse, Adriana C. Rossi, Ruben Niesvizky
Journal: Blood (2019)
The health of the nation
Authors: I. Basnett
Journal: BMJ (1991)

Alcohol consumption during pregnancy and infants' development SIR,-In their study Dr F Forrest and colleagues tried to find a relation between alcohol intake during pregnancy and infants' development.'Other factors, however, had to be taken into consideration, such as maternal smoking.Using the Bayley scales of infant development, the authors showed that the mental index was lower (-6 units) for children whose mothers smoked 10-19 cigarettes a day and (-3 units) for those whose mothers smoked .'20cigarettes a day.What I would have liked to know is the clinical importance or consequence of this lower score and whether a child with the lower score is within or outside the normal range for age.If she or he is
RTHP-25. TTFIELDS DOSE DISTRIBUTION ALTERS TUMOR GROWTH PATTERNS: AN IMAGING-BASED ANALYSIS OF THE RANDOMIZED PHASE 3 EF-14 TRIAL
Authors: Martin Glas, Suriya Jeyapalan, Scott Soltys, Andreas Hottinger, Steven A Toms, Shay levi, Gitit Lavy-Shahaf, Noa Urman, Erqi Pollum, Matthew Ballo
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION A recent post-hoc analysis of the EF-14 phase 3 trial showed a connection between TTFields dose at the tumor and Overall Survival in new diagnosed Glioblastoma (ndGBM) patients [1]. Here we expand the results of that study and show a connection between TTFields dose distribution in the brain and progression patterns in ndGBM patients. METHODS Participants of the EF-14 trial who exhibited radiological progression were included in this study (treatment: N=306/466, control: N=122/229). Enhancing tumor was segmented on T1c MRIs at baseline and progression. Regions of progression disconnected from the original lesion were defined as distal. The rates of occurrence and distances of distal progressions from primary lesions were compared between the arms. Computational head models were created and delivery of TTFields numerically simulated for n=229 patients in treatment for over 2. Dose in regions of progression was compared to dose in regions where no progression occurred. RESULTS The median distance between primary and distal lesions was larger in the treatment arm (control: 14.2±14.4 mm, TTFields 23.2±29.8 mm, p=0.03 Wilcoxon rank-sum). A higher rate of distal progression outside of a 20mm boundary zone around the primary lesion was observed in the treatment arm. (Control: 10/122, TTFields: 53/306 p&lt; 0.02 chi-squared). In proximity to the primary lesion (a 3 mm ring around the tumor), TTFields dose was lower in regions of progression than in regions where no progression occurred (0.73 mW/cm^3 vs. 0.79 mW/cm^3 p&lt; 0.0001 t-test) DISCUSSION AND CONCLUSIONS This study suggests that TTFields alters progression patterns and that progression is more likely to occur in regions exposed to low TTFields dose. The study emphasizes the rationale for adaptive TTFields treatment planning targeting regions of progression. [1] Ballo et. al., IJROBP (2019)
PATH-02. A COMBINATION OF MGMT METHYLATION AND NFKBIA COPY NUMBER ALTERATION REFINES PROGNOSTICATION OF IDH-WT GLIOBLASTOMAS
Authors: Toru Umehara, Hideyuki Arita, Ema Yoshioka, Tomoko Shofuda, Manabu Kinoshita, Yoshinori Kodama, Naoki Kagawa, Yoshiko Okita, Masahiro Nonaka, Takehiro Uda, Junya Fukai, Daisuke Sakamoto, Kanji Mori, Haruhiko Kishima, Yonehiro Kanemura
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Recent studies have reported that NFKBIA deletion (dNFKBIA) was potentially associated with worse prognosis in glioblastoma (GBM) patients. However, no consensus has been reached to its universal prognostic value. Here, we investigated the survival impact of dNFKBIA using two primary IDH wild-type GBM cohorts: an original Japanese cohort and a dataset from The Cancer Genome Atlas (TCGA). Additionally, prognostic impact of a combination of NFKBIA copy number and MGMT methylation status was evaluated. METHOD The Japanese cohort was collected from cases registered in Kansai Molecular Diagnosis Network for CNS tumors (KNBTG). The survival impact of dNFKBIA and/or unmethylated MGMT (uMGMT) were analyzed for 212 KNBTG cases and 265 TCGA cases. The hazard ratio (HR) and p-value were computed using Cox regression analysis. RESULTS dNFKBIA was less frequently observed in KNBTG (47 cases, 22.2%) than in TCGA (84 cases, 31.7%). dNFKBIA was associated with unfavorable prognosis in KNBTG (HR 1.52, p = 0.031), while this was not validated in TCGA (HR 1.14, p=0.406). uMGMT was a common adverse prognostic factor in KNBGT (HR 1.72, p = 0.001) and TCGA (HR 1.50, p = 0.008) cohort. When stratified by NFKBIA status, uMGMT was also associated with shorter survival in NFKBIA deleted cases both in KNBTG (HR 1.87, p = 0.002) and TCGA (HR 1.59, p = 0.014). On the other hand, MGMT status was not significantly associated with prognosis in NFKBIA intact cases in either KNBTG (HR 1.45, p = 0.279) or TCGA (HR 1.55, p = 0.131). DISCUSSION Although the prognostic value of dNFKBIA in IDH wild-type GBM patients was not validated in TCGA cohort, our results indicated that the prognostication based on MGMT methylation was potentially interacted by NFKBIA status.
HOUT-23. ADULT MEDULLOBLASTOMA TREATMENT IMPACT SINCE 2006: A CANADIAN UNIVERSITY CENTER EXPERIENCE
Authors: Maria Camila Quinones Ninos, Karl Belanger, Emilie Lemieux Blanchard, Bernard Lemieux, Jean-Paul Bahary, Laura G Masucci, David Roberge, Cynthia Menard, Carole Lambert, Robert Moumdjian, France Berthelet, Marie Florescu
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Medulloblastoma (MB) is an aggressive primary brain tumor rare in adults. Prospective studies in adults are limited by the small number of patients. METHODS We retrospectively reviewed all MB patients treated at the CHUM between 2006 and 2017 in our clinical database adult SARDO. We don’t have the children follow up. We divided our cohort in 2 groups, those diagnosed between 2006–2013 and those diagnosed between 2014–2017. RESULTS 49 patients were treated, 23 (47%) were children referred for radiation only from a pediatric center and 26 (53%) were adults. Median follow up of adults was 26 months. At 5 years, the entire cohort OS was 58%, but specifically for adults, the 5yOS was 80%. First line therapy had a 5y PFS 77% for adults, negatively influenced by the absence of adjuvant radiotherapy (83% vs 0%; p &lt; 0.001) and the absence of adjuvant chemotherapy (80% vs 39%; p &lt; 0.008). 96% of adult patients received radiotherapy and 52% of them received concomitant radiosensitizing chemotherapy with no impact on survival. Complete surgical resection was performed on 88% of patients, but the extent of resection did not have an impact on survival and did not change with time. From 2006–2013, the most common chemotherapy treatment (80%) in adults was Vincristine, Cisplatin and Lomustine. From 2014–2017, the chemotherapy was replaced by Cisplatin, Etoposide and Cyclophosphamide in 82% with no impact on survival (specific mortality for this chemo 3yOS 100% for both, 3y PFS 100%). Non Cisplatin based chemotherapy regimens were associated with decrease in PFS (67% at 3y). 78% of the progressive patients received second line chemo. CONCLUSION In our adult MB population, the demographic and tumor factors did’nt have an impact on prognosis but adjuvant radiotherapy and chemotherapy had a favorable impact on survival especially with Cisplatin, Etoposide and Cyclophosphamide regimen.
Nrf2 Null Mice Are Deficient in CD169+ Macrophages, Associated with Impaired Erythroid Response and Delayed Recovery from Acute Blood Loss
Authors: Oluwabukola Gbotosho, Maria G Kapetanaki, Mark A Ross, Samit Ghosh, Frances Weidert, Grant C. Bullock, Solomon Fiifi Ofori-Acquah, Gregory J Kato, Simon Watkins
Journal: Blood (2019)
Genomic Profiles and Subset Characterization of CD8+terminally Differentiated Effector Memory (TEMRA) Cells from Cancer Patients
Authors: Deok-Hwan Yang, Jae-Sook Ahn, Seo-Yeon Ahn, Sung-Hoon Jung, Je-Jung Lee, Hyeoung-Joon Kim, Young Rok Do, Sang Yun Song, Ga-Young Song, Hyeong Jong Kim, Theresa Kim
Journal: Blood (2019)
Laboratory Aids to Diagnosis and Therapy
Authors: Israel Davidsohn
Journal: Annual Review of Medicine (1952)

Immunohematology has been chosen as the theme for this chapter on Laboratory Aids to Diagnosis and Therapy. The idea that immunologic phenomena have a part in hematologic disorders is almost half a century old, but recent technical developments have transformed this branch of hema­ tology into a separate and distinct discipline with its own methodology. The name expresses aptly the enrichment of hematology by application of immunologic techniques to the solution of its unsolved problems. New names in medicine are attractive and unless clearly defined invite application to conditions which do not belong to them. Therefore, it may not be amiss to suggest a definition of the term  and i n this way forestall unecessary confusion. I had to attempt to define the scope of immunohematology for my own use in order to delimit the subject as­ signed f0r this chapter. Immunohematology encompasses diseases of blood of which the cause, the pathogenesis, or clinical manifestations have been shown to be determined by an antigen-antibody reaction. The various hemo­ lytic anemias, fetal erythroblastosis (hemolytic disease of the newborn), and infectious mononucleosis obviously belong here. Blood group factors are included in so far as they are responsible for hemolytic transfusion reac­ tions and fetal erythroblastosis. Acute disseminated lupus erythematosus (LE) is not a disease of the blood, but the so-called LE phenomenon should be treated here inasmuch as its immunologic character has been disclosed recently. It may well be that further progress will add other diseases to those mentioned, if antigen-antibody reactions are shown to be involved in them. For example, there are indications that thrombocytopenic purpura, or at least some forms of this disorder, may have to be included.
Cellular Kinetics of CD19 Chimeric Antigen Receptor T Cells in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma
Authors: Caixia Li, Changfeng Zhang, Ying Zhang, Xiaoyan Lou, Jinfang Zhang, Jia Chen, Xiaochen Chen, Liqing Kang, Jin Zhou, Xiangping Zong, Zhen Yang, Jiaqi Li, Wei Qi, Lei Yu, Depei Wu
Journal: Blood (2019)
Survival and Prognostic Factors in <i>C9orf72</i> Repeat Expansion Carriers
Authors: Stella A. Glasmacher, Charis Wong, Iona E. Pearson, Suvankar Pal
Journal: JAMA Neurology (2019)

The c9orf72 repeat expansion (c9 or c9orf72RE) confers a survival disadvantage in amyotrophic lateral sclerosis (ALS); its effect on prognosis in frontotemporal dementia (FTD) remains uncertain. Data on prognostic factors in c9orf72RE disorders could inform patient care, genetic counseling, and trial design.To examine prognostic factors in c9ALS, c9FTD, c9ALS-FTD, and atypical phenotypes.The MEDLINE, Embase, Amed, ProQuest, PsychINFO, CINAHL, and LILACS databases were searched between January 2011 and January 2019. Keywords used were c9orf72 and chromosome 9 open reading frame 72. Reference lists, citations of eligible studies, and review articles were also searched by hand.Studies reporting disease duration for patients with a confirmed c9orf72RE and a neurological and/or psychiatric disorder were included. A second author independently reviewed studies classified as irrelevant by the first author. Analysis began in January 2019.Data were extracted by 1 author; a further author independently extracted 10% of data. Data were synthesized in univariate and multivariable Cox regression and are displayed as hazard ratios (HR) and 95% confidence intervals.Survival after symptom onset.Overall, 206 studies reporting on 1060 patients were included from 2878 publications identified (c9ALS: n = 455; c9FTD: n = 296; c9ALS-FTD: n = 198; atypical phenotypes: n = 111); 197 duplicate cases were excluded. The median (95% CI) survival (in years) differed significantly between patients with c9ALS (2.8 [2.67-3.00]), c9FTD (9.0 [8.09-9.91]), and c9ALS-FTD (3.0 [2.73-3.27]); survival in atypical phenotypes varied substantially. Older age at onset was associated with shorter survival in c9ALS (HR, 1.03; 95% CI, 1.02-1.04; P < .001), c9FTD (HR, 1.04; 95% CI, 1.02-1.06; P < .001), and c9ALS-FTD (HR, 1.02; 95% CI, 1.004-1.04; P = .016). Bulbar onset was associated with shorter survival in c9ALS (HR, 1.64; 95% CI, 1.27-2.08; P < .001). Age at onset and bulbar onset ALS remained significant in multivariable regression including variables indicating potential diagnostic ascertainment bias, selection bias, and reporting bias. Family history, sex, study continent, FTD subtype, or the presence of additional pathogenic sequence variants were not significantly associated with survival. Clinical phenotypes in patients with neuropathologically confirmed frontotemporal lobar degeneration-TDP-43, motor neuron disease-TDP-43 and frontotemporal lobar degeneration-motor neuron disease-TDP-43 were heterogenous and impacted on survival.Several factors associated with survival in c9orf72RE disorders were identified. The inherent limitations of our methodological approach must be considered; nonetheless, the reported prognostic factors were not significantly associated with the bias indicators examined.
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Authors: Naveen Pemmaraju, Uma Borate, Melhem Solh, Gautam M. Borthakur, Amy E. DeZern, Chao Zhang, Ben Powell, Paul Severson, Kerry Inokuchi, Bernice Matusow, Jason Halladay, Ching Hsu, Paul Watkins, Jackie M. Walling, Athanasios C. Tsiatis, Alice S. Mims
Journal: Blood (2019)
A Novel Platelet-Targeting Fibrinolytic Strategy: Endocytosed Urokinase By Megakaryocytes Is Stored in α-Granules and Is Functional In Vivo in a Murine Model of Thrombosis
Authors: Hyunsook Ahn, John Tkaczynski, Khalil Bdeir, Victoria Stepanova, Douglas B. Cines, Mortimer Poncz, Sergei Zaitsev
Journal: Blood (2019)
ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)
Authors: Enrique M. Ocio, Yvonne A. Efebera, Miquel Granell, Roman Hajek, Vladimir Maisnar, Lionel Karlin, María-Victoria Mateos, Paul G. Richardson, Albert Oriol, Stefan Norin, Malin Sydvander, Jakob Obermüller, Luděk Pour
Journal: Blood (2019)
NIMG-38. RECOGNIZING DISSEMINATED NECROTIZING LEUKOENCEPHALOPATHY IN LEPTOMENINGEAL CARCINOMATOSIS PATIENTS TREATED WITH INTRATHECAL METHOTREXATE VIA OMMAYA RESERVOIR AFTER WHOLE BRAIN IRRADIATION
Authors: Andrew Conger, Thomas Scheeler, Erika Leese, Gino Mongelluzzo, Na Tosha Gatson
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Disseminated necrotizing leukoencephalopathy (DNL) is a rare complication of intrathecal (IT) methotrexate administration with a previously reported incidence of 2.8%1 in patients undergoing treatment for central nervous system leukemia or lymphoma. The purpose of this study is to estimate the incidence of DNL in a series of patients undergoing treatment for leptomeningeal carcinomatosis (LMC) and to better characterize the radiographic findings associated with DNL. METHODS A retrospective review of a prospectively gathered database of 36 LMC patients was conducted. Patients were treated with whole brain radiation and a standardized regimen of twice-weekly IT methotrexate in the context of an established IT chemotherapy clinic. Data regarding the patients’ primary cancer pathology, time from initiation of IT methotrexate to onset of DNL, and radiographic characteristics of DNL were collected. RESULTS Six of 36 patients (16.7%) developed DNL. Mean time from initiation of IT treatment to development of DNL was 6.7 months. Primary pathologies of the DNL patients were breast (3), melanoma (1), GI (1), and pancreatic neuroendocrine (1). Radiologic presentation included areas of T2 hyperintensity, T1 hypointensity with contrast-enhancement, and restricted diffusion, all consistent with acute demyelination. These radiographic changes predominantly involved the catheter tract, periventricular and deep white matter, and grey-white interface. Interpretation of the magnetic resonance imaging by radiologists was highly inaccurate with the findings interpreted as catheter infection, progression of metastatic disease, stroke, or “possible treatment effect”, but never correctly identified as DNL. CONCLUSION DNL is a rare complication of intrathecal chemotherapy but may have a higher incidence in patients undergoing aggressive management of LMC than in those being treated for central nervous system lymphoma or leukemia. Although the imaging in DNL often exhibits characteristic findings, the rarity of this pathology leads to frequent misinterpretation, potentially complicating management of LMC.
Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma
Authors: Jing Fu, Shirong Li, Chen Yang, Lewis M Brown, Stephen J Weiss, Charles G Drake, Markus Y. Mapara, Suzanne Lentzsch
Journal: Blood (2019)
Relationship between Vaso-Occlusive Crisis and Quality of Life: An Analysis of Patients with Sickle Cell Disease in the United States
Authors: Howard Z. Thom, Jason Shafrin, Edna Keeney, Lauren M. Zhao, George J Joseph, Menaka Bhor, Avery A. Rizio, Lanetta Bronté-Hall, Nirmish Shah
Journal: Blood (2019)